

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Labinger Barry</u> (Last) (First) (Middle) 400 PROFESSIONAL DR, SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Biosciences Div.</u>
	3. Date of Earliest Transaction (Month/Day/Year) 11/11/2015	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/11/2015		S		6,564	D	\$35.51 ⁽⁴⁾	30,229	D	
Common Stock ⁽¹⁾	11/11/2015		M		9,373	A	\$28.09	39,602	D	
Common Stock ⁽¹⁾	11/11/2015		S		9,373	D	\$35.5	30,229	D	
Common Stock ⁽²⁾	11/11/2015		M		10,095	A	\$20.94	40,324	D	
Common Stock ⁽²⁾	11/11/2015		S		10,095	D	\$35.5 ⁽⁴⁾	30,229	D	
Common Stock ⁽²⁾	11/12/2015		M		10,094	A	\$20.94	40,323	D	
Common Stock ⁽²⁾	11/12/2015		S		10,094	D	\$36	30,229	D	
Common Stock ⁽³⁾	11/11/2015		F		1,671	D	\$35.88	28,558	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option ⁽¹⁾	\$28.09	11/11/2015		M			9,373	03/11/2014	03/10/2021	Common Stock	9,373	\$0	0	D	
Stock Option ⁽²⁾	\$20.94	11/11/2015		M			10,095	11/11/2013	11/11/2020	Common Stock	10,095	\$0	0	D	
Stock Option ⁽²⁾	\$20.94	11/12/2015		M			10,094	11/11/2013	11/11/2020	Common Stock	10,094	\$0	0	D	

Explanation of Responses:

- Consists of an option granted under the company's stock incentive plan on March 11, 2014.
- Consists of an option granted under the company's stock incentive plan on November 12, 2013.
- Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50-\$35.59, inclusive.

Remarks:

/s/ Eric Burt, attorney-in-fact 11/13/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.